| Literature DB >> 35325158 |
Jenny S Maron1,2, Michelle Conroy2,3, Vivek Naranbai2,4, Upeka Samarakoon3, Tina Motazedi3, Jocelyn R Farmer1,2,3, Esther Freeman2,5, Aleena Banerji2,3, Yannic C Bartsch1, David J Gregory2,6,7, Mark C Poznansky2,6, Galit Alter1,2, Kimberly G Blumenthal2,3.
Abstract
Allergic symptoms after messenger RNA (mRNA) coronavirus disease 2019 (COVID-19) vaccines occur in up to 2% of recipients. Compared to nonallergic controls (n = 18), individuals with immediate allergic reactions to mRNA COVID-19 vaccines (n = 8) mounted lower immunoglobulin G1 (IgG1) to multiple antigenic targets in severe acute respiratory syndrome coronavirus 2 spike following vaccination, with significantly lower IgG1 to full-length spike (P = .04). Individuals with immediate allergic reactions to mRNA COVID-19 vaccines bound Fcγ receptors similarly to nonallergic controls. Although there was a trend toward an overall reduction in opsonophagocytic function in individuals with immediate allergic reactions compared to nonallergic controls, allergic patients produced functional antibodies exhibiting a high ratio of opsonophagocytic function to IgG1 titer.Entities:
Keywords: COVID-19; Moderna; Pfizer; SARS-CoV-2; anaphylaxis; humoral immunity; hypersensitivity; messenger RNA; systems serology; vaccination
Mesh：
Substances：
Year: 2022 PMID： 35325158 PMCID： PMC8992327 DOI： 10.1093/infdis/jiac107
Source DB: PubMed Journal: J Infect Dis ISSN： 0022-1899 Impact factor: 7.759